Clinical Trial Update: Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects [Phase 1]

View source ↗

Summary

Phase 1 proof-of-concept study evaluating the safety and preliminary efficacy of EDP239 in adults with hepatitis C; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• EDP239 (EDP239)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED